Robotic Surgical Procedures Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Robotic Surgical Procedures Market Trends and Insights

Expanded Clinical Validation Beyond Urology

The robotic surgical procedures market is transitioning from its reliance on urology to broader adoption across multiple specialties. In 2026, enhanced guidelines for Aquablation increased confidence in robotic treatments for benign prostatic hyperplasia, driving its use in urology. General surgery and gynecology are also gaining traction, with Johnson & Johnson's FORTE study meeting safety and performance benchmarks in a 30-patient gastric bypass cohort. Stable robotic performance in complex bariatric cases is expected to encourage payers and providers to extend adoption to related procedures, expanding the market's potential.

AI-Enabled Surgical Planning and Workflow Standardization

Artificial intelligence is transforming the robotic surgical procedures market from hardware-driven purchases to workflow-focused models. Medtronic’s Stealth AXiS system, cleared by the FDA in February 2026 and CE Mark in April 2026, integrates planning, navigation, and robotic execution into a single platform. Moon Surgical’s Maestro Software Version 2.7, launched in June 2026, introduced automated operating room setup, navigation, and post-procedure documentation. These advancements simplify operations, making robotic systems more appealing to facilities previously deterred by staffing complexities.

Ambulatory Surgical Center Platform Fit and Throughput

Ambulatory surgical centers (ASCs) are reshaping the robotic surgical procedures market, challenging the dominance of large hospitals. Stryker’s Mako RPS, launched in February 2026, targets total knee arthroplasty in outpatient settings with limited space and staffing. Similarly, Smith+Nephew’s CORI XT handheld robotics platform completed its first clinical cases in June 2026 at an ASC in Arizona. These innovations highlight the market's shift toward compact, multi-procedure systems, with vendors focusing on smaller setups and faster room turnovers to meet ASC demands.

Value-Based Procurement Tied to Measurable Outcomes

Procurement strategies in the robotic surgical procedures market are evolving, with hospitals prioritizing systems that enhance efficiency, throughput, and outcomes over upfront costs. Platforms with proven efficacy in specific procedures are gaining preference, while leasing and usage-based models are becoming more popular. These flexible options enable hospitals to align robotic adoption with case volumes and procedural needs, lowering barriers for mid-sized facilities to enter the market.

High Capital and Recurring Per-Procedure Cost Burden

Robotic surgical procedures grapple with significant cost hurdles, hindering their uptake beyond major medical centers. The financial strain extends beyond just acquiring the robotic system; costs for instruments, disposables, and upgrades play a pivotal role in the economics of each procedure. This challenge intensifies when insurers don't offer premium reimbursements for robotic surgeries compared to their laparoscopic counterparts. Consequently, medical providers are left to advocate for robotic adoption based on efficiency and patient outcomes rather than direct financial incentives. A case in point is Smith+Nephew’s CORI XT platform, which, while expanding capabilities to shoulder surgeries, introduces a substantial capital challenge for facilities still ramping up their orthopedic volumes. Consequently, adoption of robotic procedures is largely confined to tertiary hospitals, specialized clinics, and a select few busy outpatient centers.

OR Integration Complexity and Staff Training Dependencies

Adoption of robotic surgical procedures is further hampered as facilities grapple with integrating these systems into established operating room protocols. Smaller surgical teams, with limited capacity, find it challenging to accommodate training sessions, staff rotations, and the inevitable temporary dips in productivity. This challenge is magnified in ambulatory settings, where streamlined staffing is crucial for cost management, leaving little room for redundancy during training. Thus, the market for robotic surgical procedures hinges not just on advanced devices, but also on simplified setups, optimized workflows, and effective team training. If any of these elements falter, hospitals might postpone adopting the technology, even with a clear clinical interest.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Application: Urology Anchors Revenue as Orthopedics Accelerates

In 2025, urology accounted for 31.76% of the robotic surgical procedures market, maintaining its position as the leading application segment. This dominance stems from the widespread adoption of robotic prostatectomies and faster clinical acceptance compared to other specialties. The growing guideline support for Aquablation in 2026 further strengthened robotic urologic care's role in the market. Hospitals find this segment appealing as they can increase procedure volumes without creating new clinical categories.

Orthopedics is the fastest-growing segment, with a forecast CAGR of 17.90% through 2031. Recent advancements have reduced system footprints, image dependency, and setup challenges, enabling orthopedic robots to move into outpatient settings. Stryker’s Mako RPS and Smith+Nephew’s CORI XT exemplify this shift. General surgery and gynecology are also expanding, with OTTAVA’s FDA submission in January 2026 and positive gastric bypass study results signaling broader platform applications. Neurosurgery and spine remain smaller segments, but Medtronic’s Stealth AXiS demonstrates how shared platforms can enhance hospitals' capital efficiency.

By Procedure Type: Endoscopic Gains Ground as Minimally Invasive Core Holds

Minimally invasive laparoscopic robotic-assisted procedures held 26.87% of market revenue in 2025, maintaining their leadership position. This reflects the established history of robotic surgeries in urology, gynecology, and general surgery. Intuitive Surgical reported a 12% year-over-year increase in globally installed da Vinci systems, reaching 11,395 units by March 2026. The company’s Q1 2026 revenue of USD 2.77 billion, with a 23% rise in instruments and accessories sales, underscores the segment's financial stability driven by recurring procedures. The laparoscopic core remains robust due to its scale, training base, and reimbursement familiarity.

Endoscopic robotic procedures are the fastest-growing segment, with a projected CAGR of 18.25% through 2031. Miniaturized tools are driving growth by enabling natural-orifice and transluminal procedures that older systems could not address effectively. Percutaneous and catheter-based robotic procedures are gaining traction in cardiology and interventional oncology, while open-assisted hybrid procedures remain relevant in lower-resource settings. Over time, the market is expected to integrate laparoscopic, endoscopic, and hybrid workflows as vendors develop broader platform families.

By End User: Specialty Clinics Lead While ASCs Redefine the Growth Frontier

Specialty clinics accounted for 25.45% of the robotic surgical procedures market in 2025, making them the leading end-user segment. Their dominance is driven by high-volume urologic and orthopedic procedures, where robotic use is justified by throughput and patient acquisition. Focused outpatient practices align surgeon specialization, case flow, and equipment utilization more effectively than diversified hospital operating rooms, making robotic investments sustainable for procedures like robotic prostatectomies and knee arthroplasties. Standalone and private hospitals remain key buyers but face increasing pressure to demonstrate cost control and improved outcomes.

Ambulatory surgical centers (ASCs) are the fastest-growing end-user segment, with a forecast CAGR of 17.69% through 2031. The market is expanding into ASCs due to systems designed for smaller spaces, reduced staffing needs, and faster room turnovers. Stryker’s Mako RPS was used for the first total knee arthroplasty at the Surgery Center at Pelham in early 2026, showcasing the ASC robotics model. Similarly, Smith+Nephew’s CORI XT cases in Arizona ASCs highlight the growing adoption of outpatient orthopedic robotics. While large hospitals will continue to handle complex multi-specialty robotic procedures, future growth is expected to shift toward ASCs and specialty clinics.

Geography Analysis

In 2025, North America accounted for 43.55% of the robotic surgical procedures market, maintaining its position as the largest regional contributor. The region benefits from strong reimbursement frameworks in robotic urology, higher utilization rates per installed system, and a well-established training base for surgeons and care teams. Intuitive reported a 15% increase in US da Vinci procedures in 2025, alongside a 31% rise in after-hours procedure utilization in Q1 2026. This indicates that market growth is driven by better utilization of existing systems rather than solely by new installations. While Canada and Mexico are progressing, the US continues to lead the region in terms of volume, reimbursement, and platform approvals.

Europe held the second-largest share in the robotic surgical procedures market. The region benefits from strong clinical research, universal healthcare systems, and a significant manufacturing presence. However, reimbursement remains less consistent compared to North America, exposing hospitals to higher economic risks when robotic benefits are not fully covered under existing payment structures. Despite this, Europe is advancing through selective platform adoption, particularly in orthopedic and minimally invasive applications, which support long-term utilization. Success in Europe under tighter budget constraints strengthens vendors' prospects for broader global adoption.

Asia-Pacific is projected to witness the fastest growth in the robotic surgical procedures market, with a CAGR of 17.45% through 2031. The region is transitioning from import reliance to stronger domestic competition, especially in China. Da Vinci procedures in Southeast Asia grew by 24% in 2025, reflecting increased utilization even in markets with smaller installed bases compared to North America and Europe. China's domestic surgical robot market is gaining traction, potentially reshaping pricing and platform access. India and South Korea contribute to regional growth through rising chronic disease burdens and private hospital investments, while the Middle East, Africa, and South America remain in early stages, focusing on medical tourism, hospital modernization, and selective platform adoption.